Royalty Pharma plc
Royalty Pharma plc (Nasdaq: RPRX) acquires and funds biopharmaceutical royalties, receiving payments tied to the sales of therapies developed or marketed by others. It works with participants across the life sciences industry, including academic institutions, research hospitals, nonprofits, biotechnology companies and… From the company’s description.
In fiscal 2025, Royalty Pharma plc reported revenue of $2.38B, up 5.1% from fiscal 2024, and net income of $1.32B. Its operating margin was 65.6%, and operations generated $2.49B in cash. Over the twelve months to Jun 30, 2026, revenue was $2.54B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Royalty Pharma plc does
In the company’s own words
Royalty Pharma plc (Nasdaq: RPRX) acquires and funds biopharmaceutical royalties, receiving payments tied to the sales of therapies developed or marketed by others. It works with participants across the life sciences industry, including academic institutions, research hospitals, nonprofits, biotechnology companies and global pharmaceutical companies, providing capital through purchases of existing royalties, newly created royalties and other funding arrangements. Its portfolio includes royalties on more than 35 marketed products and 20 development-stage candidates, with therapies spanning rare diseases, neuroscience, oncology, immunology, respiratory conditions and other areas. Major royalty interests include Vertex’s cystic fibrosis therapies, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, and Pfizer and Astellas’ Xtandi. Royalty Pharma reported $3.3 billion in Portfolio Receipts in 2025 and had 100 employees as of December 31, 2025. Founded in 1996, the company internalized its former external manager in 2025. Its website is www.royaltypharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1802768
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Royalty Pharma plc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Royalty Pharma plc · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Royalty Pharma plc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Royalty Pharma plc’s bonds, as funds hold them
Funds report holding 12 issues of Royalty Pharma plc’s debt, $1.31B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.65%, maturing 2027 to 2055.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Royalty Pharma plc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Royalty Pharma plc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Royalty Pharma plc's last four quarterly filings that the numbers alone won't show?”